BioSpace News Archive

Biotech Bay

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

Alterity Therapeutics today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, 22 June 2023 at 10:30 a.m. AFST.

June 21, 2023
·
1 min read
Drug Development

Versanis Bio Announces Completion of Enrollment of the BELIEVE Phase 2b Study in Patients with Obesity

Versanis Bio (“Versanis”), a clinical-stage biopharmaceutical company advancing novel therapeutics for obesity and other cardiometabolic diseases, today announced that BELIEVE (NCT05616013), a global Phase 2b study in patients with obesity, has completed enrollment, with 507 patients randomized.

June 21, 2023
·
3 min read
Drug Development

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, announced the presentation of compelling preclinical data at the Cellicon Valley 2023 Meeting in Philadelphia, PA.

June 21, 2023
·
2 min read
UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa

UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study with oral orismilast in adult patients with HS.

June 21, 2023
·
6 min read
Drug Development

Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023

Boston Pharmaceuticals announced positive Phase 2a results for BOS-580, its investigational, proprietary, long-acting fibroblast growth factor 21 analog for the treatment of non-alcoholic steatohepatitis.

June 21, 2023
·
5 min read
Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)

The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE, with FNP122 in amyotrophic lateral sclerosis.

June 21, 2023
·
2 min read
Deals

Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical

Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business.

June 21, 2023
·
8 min read
BioMidwest

Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv.

June 21, 2023
·
3 min read
Genetown

Novotech Selected for Biotech CRO Leadership Award 2023

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities has been selected for the prestigious CRO Leadership Award 2023 for exceeding biotech customer expectations in the “Compatibility” category.

June 21, 2023
·
2 min read
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

InflaRx N.V. announced today the commercial launch of Gohibic (vilobelimab) in the U.S.

June 21, 2023
·
11 min read